EMA Authorised: Filsuvez (dry extract from birch bark (DER 5-10 : 1), extraction solvent n-heptane 95% (w/w)) — Chiesi Farmaceutici S.p.A

View source ↗

Summary

EMA authorised Filsuvez for epidermolysis bullosa dystrophica and junctional forms; the marketing authorization holder is Chiesi Farmaceutici S.p.A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermolysis Bullosa Dystrophic
• Epidermolysis Bullosa Junctional

Drugs mentioned

• Filsuvez (beremagene geperpavec)

Snippet

Status: Authorised. Therapeutic area: Epidermolysis Bullosa Dystrophica;Epidermolysis Bullosa, Junctional. MAH: Chiesi Farmaceutici S.p.A. Decision date: 15/05/2025. Orphan medicine